Johnson & Johnson earnings beat expectations despite legal challenges from opioids and talc
Johnson & Johnson on Tuesday reported third-quarter earnings and revenue that beat expectations, boosted by higher sales of cancer and other prescription drugs, despite multimillion-dollar legal problems from talc and opioids. Here’s what the company reported compared with Wall Street estimates, based on a survey of analysts by Refinitiv: Adjusted earnings per share: $ 2.12… Read More: Johnson & Johnson earnings beat expectations despite legal challenges from… »